Just a couple of deals in a couple of days for Catalent.
The New Jersey-based CDMO’s latest move is a long-term supply agreement with Erytech Pharma, a French clinical-stage biopharma, and the purchase of its cell therapy manufacturing site in the motherland.
The deal is good for $44.5 million, and 40 of Erytech’s Princeton, NJ employees will be offered employment by the site’s new owner. Catalent will now make Erytech’s lead candidate Graspa for clinical and commercial supply in the US.
